to leverage mutational antigenic profiling to advance the design of vaccines and therapeutics to SARS-CoV-2, influenza virus and HIV | Pandemic PACT Tracker

Key facts

Disease
COVID-19, Unspecified
start year
2020
Known Financial Commitments (USD)
$899,997
Funder
Gates Foundation
Principal Investigator
N/A
Research Location
United States of America
Lead Research Institution
Fred Hutchinson Cancer Center
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen genomics, mutations and adaptations
Special Interest Tags
N/A
Study Type
Not applicable
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:42 minutes ago

View all publications at Europe PMC

Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.

The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes.

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.